Skip to main content
Eurostyle Collection Lisboa Table Lamp by Gilt <img src="https://chart.googleapis.com/chart?cht=qr&chs=200x200&chl=https%3A%2F%2Fapi.shopstyle.com%2Faction%2FapiVisitRetailer%3Fid%3D687775003%26pid%3Duid1456-40284116-11%26utm_content%3Dqr-code">
Post a Comment

ALL ABOUT MS Treatment (Part 9)

ALL ABOUT MS  Treatment (Part 9)

Glatiramer acetate (Copaxone)

This drug has similar effects and indications as interferon beta but a slightly different mechanism of action. It is applied at a dose of 20 mg, daily, subcutaneously. Side effects are also somewhat different, and include skin changes at the drug site and transient and short-term feeling of tightness in the chest with heart palpitations and a sense of lack of air.

Natalizumab (Tysabri)

This medicine is administered intravenously once a month. It works by preventing the immune system's entry into the brain and thus reducing the inflammatory (inflammatory) effect of immune cells on the nerve cells. Clinical trials have shown that natalizumab significantly reduces the incidence of attacks in the relapse form of MS, but in three patients it has caused a rare, but often fatal, brain disease. After this, the drug was withdrawn from the market, but in 2006 it was returned because of its positive effects on patients with MS. Now, the use of natalizumab is advised under strictly controlled conditions, and only in patients who do not respond positively to any other therapy.

Mitoxantrone (Novantrone)

Mitoxantron is a cytostatic (used in chemotherapy of many types of cancers), which is used in small doses to treat aggressive forms of relapse-remotent form of MS and certain forms of progressive form of MS. It is administered intravenously, every three months. Since mitoxantrone can cause serious side effects after prolonged use, such as heart failure, does not apply for more than two to three years.

Some doctors prescribe some other chemotherapeutic drugs, such as cyclofosfamide (Cytoxan), in the event of a serious, rapidly progressing disease. However, this drug has not been approved by the World Drug Treatment Agency for MS.

Plasmafereza


Plasmafereza is a method that successfully treats autoimmune diseases. However, it is not yet clear whether its use results in short-term or long-term results in MS treatment, and its use is still contested. Plasmapheresis can help restore neurological functions in patients with sudden severe attacks that do not respond to high-dose steroids.
Labels:

Comments

Post a Comment

Popular posts from this blog

ALL ABOUT MS Treatment (Part 8)

Treatment Since research has shown that MS is an autoimmune disease, two basic approaches, immunosuppression (weakening of the immune response of the organism) and immunomodulation (changing the immune response) are used in the treatment. Numerous studies have shown that in the treatment of MS, the following drugs have success: interferon beta (betaferon, rebif, avonex), glatiramer acetate (copaxone), natalizumab (tysabri), mitoxantrone (novantrone) and some other cytostatics. Interferon beta Interferon beta is a protein that is a natural component of the human organism and is created by the cells of our immune system during defense reactions to external agents, primarily viruses. However, the most important effect this protein has is the so-called. Immunomodulatory effect: interferon beta promotes processes that mitigate the effects and slow down the ankle of multiple sclerosis, while the opposite inhibits it. The exact mechanism by which the interferon beta acts the...
Post a Comment
Read more

ALL ABOUT MS Symptoms of MS (Part 4)

Urinary disorders About one-third of patients have sphincter disorders: an overwhelming need for urinary incontinence, which can sometimes be accompanied by frequent urination (so-called polacizuria), difficulty in urinating, retention (complete inability to urinate) and incontinence (loss of control over the process urinating, so that the urinary bladder empties reluctantly and unexpectedly). Urinary disorders can be accompanied by constipation and incontinence of the stool and impotence. Urinary disorders are very disturbing disorders, which significantly affect the quality of life, personal, professional and social functioning of the patients. Urinary disorders in MS are very common and occur in approximately 96% of patients with MS after 10 years of illness. Urinary disorders can occur at any time during the course of the disease, even at its inception (in about 2% of patients). Some researchers believe that patients in whom the disease begins with problems in the...
Post a Comment
Read more